153 related articles for article (PubMed ID: 14678246)
1. In silico insights: chemical and structural characteristics associated with uridine diphosphate-glucuronosyltransferase substrate selectivity.
Smith PA; Sorich MJ; McKinnon RA; Miners JO
Clin Exp Pharmacol Physiol; 2003 Nov; 30(11):836-40. PubMed ID: 14678246
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the in silico modelling of UDP glucuronosyltransferase substrates.
Sorich MJ; Smith PA; Miners JO; Mackenzie PI; McKinnon RA
Curr Drug Metab; 2008 Jan; 9(1):60-9. PubMed ID: 18220572
[TBL] [Abstract][Full Text] [Related]
3. The importance of local chemical structure for chemical metabolism by human uridine 5'-diphosphate-glucuronosyltransferase.
Sorich MJ; McKinnon RA; Miners JO; Smith PA
J Chem Inf Model; 2006; 46(6):2692-7. PubMed ID: 17125209
[TBL] [Abstract][Full Text] [Related]
4. Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity.
Sorich MJ; Miners JO; McKinnon RA; Smith PA
Mol Pharmacol; 2004 Feb; 65(2):301-8. PubMed ID: 14742671
[TBL] [Abstract][Full Text] [Related]
5. Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes.
Dong D; Ako R; Hu M; Wu B
Xenobiotica; 2012 Aug; 42(8):808-20. PubMed ID: 22385482
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates.
Sorich MJ; Smith PA; McKinnon RA; Miners JO
Pharmacogenetics; 2002 Nov; 12(8):635-45. PubMed ID: 12439224
[TBL] [Abstract][Full Text] [Related]
7. Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases.
Smith PA; Sorich MJ; Low LS; McKinnon RA; Miners JO
J Mol Graph Model; 2004 Jul; 22(6):507-17. PubMed ID: 15182810
[TBL] [Abstract][Full Text] [Related]
8. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.
Miners JO; Mackenzie PI; Knights KM
Drug Metab Rev; 2010 Feb; 42(1):196-208. PubMed ID: 19795925
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional studies of UDP-glucuronosyltransferases.
Radominska-Pandya A; Czernik PJ; Little JM; Battaglia E; Mackenzie PI
Drug Metab Rev; 1999 Nov; 31(4):817-99. PubMed ID: 10575553
[TBL] [Abstract][Full Text] [Related]
10. The effects of UDP-sugars, UDP and Mg
Walia G; Smith AD; Riches Z; Collier AC; Coughtrie MWH
Xenobiotica; 2018 Sep; 48(9):882-890. PubMed ID: 28868965
[TBL] [Abstract][Full Text] [Related]
11. Insights into the UDP-sugar selectivities of human UDP-glycosyltransferases (UGT): a molecular modeling perspective.
Nair PC; Meech R; Mackenzie PI; McKinnon RA; Miners JO
Drug Metab Rev; 2015 Aug; 47(3):335-45. PubMed ID: 26289097
[TBL] [Abstract][Full Text] [Related]
12. Glucuronidation in humans. Pharmacogenetic and developmental aspects.
de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
Clin Pharmacokinet; 1999 Jun; 36(6):439-52. PubMed ID: 10427468
[TBL] [Abstract][Full Text] [Related]
13. Backbone assignment of the apo-form of the human C-terminal domain of UDP-glucuronosyltransferase 1A (UGT1A).
Osborne MJ; Coutinho de Oliveira L; Volpon L; Borden KLB
Biomol NMR Assign; 2018 Oct; 12(2):315-318. PubMed ID: 29934866
[TBL] [Abstract][Full Text] [Related]
14. Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry.
Badée J; Qiu N; Parrott N; Collier AC; Schmidt S; Fowler S
Drug Metab Dispos; 2019 Feb; 47(2):124-134. PubMed ID: 30478159
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
Smith PA; Sorich MJ; McKinnon RA; Miners JO
J Med Chem; 2003 Apr; 46(9):1617-26. PubMed ID: 12699380
[TBL] [Abstract][Full Text] [Related]
16. Structure and function of uridine diphosphate glucuronosyltransferases.
Meech R; Mackenzie PI
Clin Exp Pharmacol Physiol; 1997 Dec; 24(12):907-15. PubMed ID: 9406655
[TBL] [Abstract][Full Text] [Related]
17. In silico site of metabolism prediction for human UGT-catalyzed reactions.
Peng J; Lu J; Shen Q; Zheng M; Luo X; Zhu W; Jiang H; Chen K
Bioinformatics; 2014 Feb; 30(3):398-405. PubMed ID: 24273240
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the zebrafish Ugt repertoire reveals a new class of drug-metabolizing UDP glucuronosyltransferases.
Wang Y; Huang H; Wu Q
Mol Pharmacol; 2014 Jul; 86(1):62-75. PubMed ID: 24728488
[TBL] [Abstract][Full Text] [Related]
19. Establishment of pharmacophore and VolSurf models to predict the substrates of UDP-glucuronosyltransferase1A3.
Wu Z; Zhang X; Ma Z; Wu B
Xenobiotica; 2015; 45(8):653-62. PubMed ID: 25837689
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of uridine diphosphate on UDP-glucuronosyltransferase.
Yokota H; Ando F; Iwano H; Yuasa A
Life Sci; 1998; 63(19):1693-9. PubMed ID: 9806225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
